Coherent sees new laser as standard treatment for glaucoma:
This article was originally published in Clinica
Executive Summary
In a pilot study of its new Selecta 7000 laser, Coherent found that it reduced the pressure associated with open-angle glaucoma by 30% on the first day of treatment, and that the benefit lasted for one year of follow-up. These initial results have encouraged the company to believe its technique, selective laser traberculoplasty, could become a standard treatment. The company is to begin shipment of the laser outside the US and will pursue clinical investigations in the US and Japan.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.